Clinical Publications |
Scientific Publications |
July 2025 |
A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: A narrative review Ghasoub R et al. Front Oncol, July 2025 – open access publication
|
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to allosteric ABL inhibitor asciminib Muratcioglu S et al. Sci Signal, July 2025 (epub ahead of print) – open access publication |
Using early biomarker change and treatment adherence to predict risk of relapse among patients with chronic myeloid leukemia who are in remission Montano-Campos JF et al. JCO Clin Cancer Inform, July 2025
|
Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia Yang H et al. Clin Epigenetics, July 2025 – open access publication |
Comparing therapeutic effects across tyrosine kinase inhibitors: Chronic myeloid leukemia outcomes and analysis of influencing factors Zhang Z et al. Medicine(Baltimore), July 2025
|
K562 chronic myeloid leukemia cells as a dual beta3-expressing functional cell line model to investigate the effect of combined alphaIbbeta3 and alphavbeta3 antagonism Elsharif AA et al. Methods Protoc, July 2025 – open access publication
|
Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy Hayashino K et al. Int J Hematol, July 2025 (epub ahead of print) |
CHK1-S, a splicing variant of CHK1, suppresses chronic myeloid leukemia Lei H et al. Leuk Res, July 2025 (epub ahead of print)
|
Measurable residual disease in hematologic malignancies: A biomarker in search of a standard Shandhok NS and Sekeres MA. EClinicalMedicine, July 2025 (epub ahead of print) |
Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells Okabe S et al. Discov Oncol, July 2025 – open access publication
|
Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia Lopez-Fernández E et al. Ann Hematol, July 2025 (epub ahead of print)
|
ZFAS1/STAT3 axis modulates imatinib resistance in chronic myeloid leukemia cells through glucose metabolism reprogramming Yang L and Han Y. Front Oncol, July 2025 – open access publication |
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors – Review Gullaksen SE et al. Leuk Lymphoma, July 2025 – open access publication
|
Identification of a PAK6-mediated MDM2/p21 axis that modulated survival and cell cycle control of drug-resistant stem/progenitor cells in chronic myeloid leukemia Wu A et al. Int J Mol Sci, July 2025 – open access publication
|
Associations between waist circumference, body mass index, HDL cholesterol level, and risk of chronic myeloid leukemia Kim KY et al. Cancer Epidemiol Biomarkers Prev, July 2025
|
Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia Ensafi Talemi F and Ghafouri-Fard S. Leuk Res Rep, July 2025 – open access publication |
June 2025 |
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: Does dose matter? - Review Dalgetty M and Cortes J. Blood, June 2025
|
miRNA expression based modulation: A new paradigm for the treatment of chronic myeloid leukemia - Review Ansari S and Varma M. Biochim Biophy Acta Rev Cancer, June 2025 (epub ahead of print) |
Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report Zhou X et al. Oncol Lett, June 2025 – open access publication
|
Metamizole limits proliferation in chronic myeloid leukemia cells and triggers apoptosis via the bax/bal-2/caspase-3 cascade Maytalman E et al. Med Oncol, June 2025 – open access publication |
Clinical features and treatment response to tyrosine kinase inhibitors in chronic myeloid leukemia patients with atypical BCR::ABL1 transcript Wang H et al Leuk Res, June 2025 (epub ahead of print)
|
Overexpression of miR-29a and miR-29b is involved in imatinib resistance via abrogated NF1 expression and increased ERK1/2 activation in chronic myeloid leukemia cells Tsubaki M et al. Med Oncol, June 2025 |
Risk factors, behavior, and adverse health outcomes of financial toxicity in adult chronic myeloid leukemia survivors: A theory-based structural equation model Jin R et al. Support Care Cancer, June 2025
|
The telomere length signature in leukemias – from molecular mechanisms underlying telomere shortening to immunotherapeutic options against telomerase Baliou S et al. Cancers(Basel), June 2025 – open access publication |
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic-phase: A prospective, observational study – SIMPLICITY Mauro MJ et al. Leuk Lymphoma, June 2025 (epub ahead of print) – open access publication |
Machine learning driven dashboard for chronic myeloid leukemia prediction using protein sequences Ahmed W et al. PLoS One, June 2025 – open access publication
|
Which is the best tyrosine kinase inhibitor for newly diagnosed chronic myelogenous leukemia? - Review Shanmunagathan N et al. Am Soc Clin Oncol Educ Book, June 2025 – open access publication |
Uncovering putative causal non-coding RNAs in acute and chronic myeloid leukemia: A genome-wide Mendelian Randomisation Study Jung S et al. Cancer Res Treat, June 2025 (epub ahead of print) – open access publication
|
Asciminib for Philadelphia chromosome-positive leukemias Hughes TP et al. Haematologica, June 2025 (epub ahead of print) – open access publication |
BCR-ABL: The mastermind behind chronic myeloid leukemia – Review Shammas T et al. Cytokine Growth Factor Rev, June 2025 – open access publication |
Treatment-free remission in chronic myeloid leukemia: Revisiting the “W” questions Bruzzese A et al. Eur J Haematol, June 2025 (epub ahead of print) – open access publication |
SUMOylation facilitates the stability of BCR-ABL to promote chronic myeloid leukemia progression Zhang L et al. Oncogene, June 2025 |
SOHO state of the art updates and next questions: Combination therapy in chronic myeloid leukemia chronic-phase – Review Costa A and Breccia M. Clin Lymphoma Myeloma Leuk, June 2025 |
Metabolomic profiling and bioanalysis of chronic myeloid leukemia: Identifiying biomarker for treatment response and disease monitoring Sayin S et al. Metabolite, June 2025 – open access publication |
Impact of tyrosine kinase inhibitors on thyroid function in chronic myeloid leukemia: A systematic review Sardarova N et al. Cureus, June 2025 – open access publication |
SMYD3 activates fatty acid beta-oxidation to promote self-renewal of leukemia stem cells Zhou M et al. Cancer Res, June 2025 |
Olverembatinib in chronic myeloid leukemia: Is less actually better? Perusini MA and Kim DDH. Haematologica, June 2025 (epub ahead of print) – open access publication |
Genetic variants in oxidative stress-related genes and their impact on prognosis and treatment response in chronic myeloid leukemia patients Alves R et al. Int J Mol, June 2025 – open access publication |
Real-world evidence of treatment-free remission strategies and outcomes in chronic myeloid leukemia Bourne G et al. Cancers(Basel), June 2025 – open access publication |
|
Innovative rapid screening for complex BCR-ABL kinase domain mutations in TKI-treated leukemia patients Lan Y et al. Br J Cancer, June 2025 (epub ahead of print) |
|
Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under conditions, such as the de novo cases: A case series of the novo CML-BC treated with ponatonib and no transplantation Koyabu S et al. Leuk Lymphoma, June 2025 |
|
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: A systematic review and meta analysis Fan Z et al. Ther Adv Hematol, June 2025 – open access publication |
|
Treatment-free remission (TFR) in chronic-phase chronic myeloid leukemia (CP-CML): Analysis of predictive factors and novel baseline scoring system to predict molecular relapse Laganà A et al Eur J Haematol, June 2025 (epub ahead of print)
|
|
May 2025 |
Chronic myeloid leukemia: A review Jabbour E and Kantarjian H. JAMA, May 2025
|
Research of the functions and potential mechanisms of STAT3 in chronic myelogenous leukemia Feng X et al. Discov Oncol, May 2025 – open access publication |
Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis - Review Smit Y et al. Support Care Cancer, May 2025 – open access publication
|
BCR-ABL: The molecular mastermind behind chronic myeloid leukemia – Review Shammas T et al. Cytokine Growth Factor Rev, May 2025 (epub ahead of print) – open access publication |
Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in CML: Insights from a multicenter retrospective study in real-world practice Hibino Y et al. Leuk Res, May 2025
|
Structure and dynamics of the ABL1 tyrosine kinase and its important role in chronic myeloid leukemia - Review Irgit A et al. Arch Pharm (Weinheim), May 2025 – open access publication |
Management of chronic-phase chronic myeloid leukemia in later lines: A Hong Kong consensus recommendation Cheung CYM et al. Ann Hematol, May 2025 (epub ahead of print)
|
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers - Review Sicuranza A et al. Front Oncol, May 2025 – open access publication |
Real world evidence from 2 decades of first-line TKI therapy in chronic myeloid leukemia (CML): Insights from ACHO’s RENEHOC Registry Abello Polo V et al. Clin Lymphoma Myeloma Leuk, May 2025 – open access publication |
BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake Mancini C et al. Cancer Cell Int, May 2025 – open access publication |
Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617F mutation by combination therapy with asciminib and ropeginterferon alpha-2b in an elderly patient Oka S et al. Int J Hematol, May 2025 (epub ahead of print)
|
GPX1 confers resistance to metabolic stress in BRC/ABL-T315I mutant chronic myeloid leukemia cells Wang JD et al. Cell Death Disc, May 2025 – open access publication |
Asciminib remained superior versus bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL Mauro MJ et al. Blood Adv, May 2025 (epub ahead of print) |
|
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patient failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trials le Coutre P et al. Acta Haematol, May 2025 (epub ahead of print) |
|
Pharmacokinetic profile of novel reduced-dose Danziten TM (Nilotinib tablets) versus Tasigna TM (Nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis Mauro MJ et al. Cancer Chemother Pharmacol, May 2025 – open access publication |
|
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC Johnson-Ansah H et al. Leuk Res, May 2025 (epub ahead of print) |
|
Real-world efficacy profile of compassionate use of asciminib in an Italian, multi-resistant chronic-phase chronic myeloid leukemia (CP-CML) patient population Breccia M et al. Hematol Oncol, May 2025 – open access publication |
|
Bosutinib for successful treatment-free remission in chronic myeloid leukemia Fujioka Y et al. Cancer Med, May 2025 – open access publication |
|
Optimal depth of the treatment response before allogeneic hematopoietic transplantation for chronic myeloid leukemia in chronic phase Okada Y et al. Am J Hematol, May 2025 (epub ahead of print) – open access publication |
|
Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia: A review Jajosky AN and Lichtman MA. Haematologica, May 2025 (epub ahead of print) – open access publication
|
|
April 2025 |
Chronic myeloid leukemia Treatment (PDQ): Patient Version PDQ Adult Treatment Editorial Board, April 2025 – open access publication
|
KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT(+) blast phase chronic myeloid leukemia Kwon HJ et al. Mol Cancer, April 2025 – open access publication
|
Molecular response with Ascminib 20 mg QD in a patient intolerant to multiple TKIs Stuckey R et al. Ann Hematol, April 2025 (epub ahead of print) – open access publication
|
High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia Nygrén P et al. Blood, April 2025 – open access publication
|
Asciminib monotherapy in patients with chronic myeloid leukemia chronic-phase without BCR::ABL1 T315I treated with at least 2 prior tyrosine kinase inhibitors: Phase 1 final results Hochhaus A et al. Leukemia, April 2025 (epub ahead of print) – open access publication |
A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia Bica V et al. Cell Commun Signal, April 2025 – open access publication |
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: Phase 1 study final results Cortes JE et al. Leukemia, April 2025 (epub ahead of print) – open access publication |
The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis Thuy VT et al. Leuk Res, April 2025 |
Olverembatinib in chronic myeloid leukemia – Review of historical development, current status, and future research Kantarjian H et al. Cancer, April 2025 |
Dysregulation of sphingolipid metabolism contributes to the pathogenesis of chronic myeloid leukemia Xie Y et al. Cell Death Dis, April 2025 – open access publication
|
Successful treatment-free remission after ponatinib discontinuation in pretreated patients with chronic myeloid leukemia in chronic-phase Haddad FG et al. Clin Lymphoma Myeloma Leuk, April 2025 |
SMAC mimetics in action in chronic myeloid leukemia Turhan AG. Blood, April 20 |
CAR-T cell therapy in chronic myeloid leukemia patients with lymphoid blast crisis: A multicenter clinical analysis Liu Y et al. Cancer Lett, April 2025 (epub ahead of print) |
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability Mancini M et al. Clin Transl Med, April 2025 – open access publication |
Prognostic scoring system in chronic myeloid leukemia – Review Lauseker M et al. Leukemia, April 2025 (epub ahead of print) – open access publication |
Timing and trajectory of BCR::ABL1-driven chronic myeloid leukemia Kamizela AE et al. Nature, April 2025 – open access publication |
How I individualize treatment for chronic-phase CML Leyte-Vidal AM and Shah NP. Blood, April 2025 (epub ahead of print) |
|
Synergistic effect of asciminib with reduced doses of ponatinib in human Ph+ myeloid leukemia with the T315M mutation Nguyen T et al. Int J Hematol, April 2025 (epub ahead of print) – open access publication |
|
Tyrosine kinase inhibitor treatment patterns in patients with chronic-phase chronic myeloid leukemia: A single centre data from China Yuan MY et al. Clin Lymphoma Myeloma Leuk, April 2025 |
|
Incidence of cardiovascular events and carotid artery USG abnormalities in chronic myeloid leukemia patients on nilotinib therapy: A 20-year single center study Jang Y et al. Clin Lymphoma Myeloma Leuk, April 2025 (epub ahead of print) |
|
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia Zhang X et al. Haematologica, April 2025 (epub ahead of print) – open access publication |
|
March 2025 |
Twin pregnancy during treatment with asciminib for chronic myeloid leukemia – a care report Gutierrez de Moraes Pereira GBBM. Ann Hematol, March 2025 (epub ahead of print) – open access publication
|
PTBP2 promotes cell survival and autophagy in chronic myeloid leukemia by stabilizing BNIP3 Barik B et al. Cell Death Dis, March 2025 – open access publication
|
Nilotinib induced diabetes in Japanese patients with chronic myeloid leukemia Iwamoto Y et al. Intern Med, March 2025 – open access publication
|
Different in vitro models of chronic myeloid leukemia show different characteristics: Biological replicates are not biologically equivalent Cavalleri A et al. Cell Biol Int, March 2025 (epub ahead of print) – open access publication |
Severe acute cutaneous-only graft-versus-host disease after late relapse of chronic myeloid leukemia and ultraviolet B photography Beeler JS et al. Haematologica, March 2025 – open access publication
|
Comprehensive analysis of tyrosine kinase inhibitor domain mutations and imatinib resistance in chronic myeloid leukemia patients Dhangar S et al. Leuk Res, March 2025 (epub ahead of print)
|
Alternative routes of drug administration: Exposure of imatinib using different formulations Fiebrich-Westra HB et al. Cancer Chemother Pharmacol, March 2025
|
Selective translational control by PABPC1 phase separation regulates blast crisis and therapy resistance in chronic myeloid leukemia Sun C et al. Nat Cell Biol, March 2025 (epub ahead of print) |
Evaluation of leukemic stem cell (CD26+) in chronic myeloid leukemia patients with different molecular response and in treatment-free remission Camado MF et al. Clin Exp Med, March 2025 – open access publication |
Asciminib: The tyrosine kinase inhibitor with a unique mode of action - Review Jain AG and Cortes JE. Expert Opin Pharmacother, March 2025 (epub ahead of print) |
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway Wang J et al. Nat Cancer, March 2025 (epub ahead of print) |
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: Does dose matter? Dalgetty M and Cortes JE. Blood, March 2025 (epub ahead of print) |
|
Imatinib and the dawn of precision cancer medicine Druker BJ. Nat Med, March 2025 |
|
Living, not just surviving with CML – quality of life to the front of the line Lipton JH and Rea D. Leukemia, March 2025 (epub ahead of print) |
|
Chronic myeloid leukemia: A review Jabbour E and Kantarjian H. JAMA, March 2025 (epub ahead of print) |
|
Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors Rodrigues Moreira P et al. J Oncol Pharm Pract, March 2025 (epub ahead of print) |
|
Do we need another TKI for chronic myeloid leukemia? Hjorth-Hansen H. Lancet Haematol, March 2025 |
|
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study Busque L et al. Blood Cancer J, March 2025 – open access publication |
February 2025 |
Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving Olverembatinib: Quality of life matters! Eşkazan AE. Cancer, February 2025 |
Autophagy and Cancer: Insights into molecular mechanisms and therapeutic approaches for chronic myeloid leukemia – Review Kausar MA et al. Biomolecules, February 2025 – open access publication
|
Novel treatment strategies for chronic myeloid leukemia – Review Cruz-Rodriguez N and Deininger MW. Blood, February 2025
|
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells Guoyun J et al. Exp Hematol, February 2025 – open access publication
|
Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia – Review Guilhot F and Hehlmann R. Blood, February 2025
|
MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Box, Puma and Noxa expression levels in imatinib-resistant chronic myeloid leukemia cells Kimura A et al. Biomed Rep, February 2025 – open access publication
|
Unrelated bone marrow transplantation for CML after liver transplantation Watanabe M et al. Intern Med, February 2025 (epub ahead of print) – open access publication
|
MiR-142 deficit in T-cells during blast crisis promotes chronic myeloid leukemia immune escape Chen F et al. Nat Commun, February 2025 – open access publication
|
Treatment-emergent resistance to asciminib in chronic myeloid leukemia patients due to myristoyl-binding pocket-mutant of BCR::ABL1/A337V can be effectively overcome with dasatinib treatment Batar P et al. Curr Oncol, February 2025 – open access publication
|
Low-dose bee venom as a potential target against human chronic myeloid leukemia cells Halici H et al. Protein J, February 2025 (epub ahead of print)
|
A CML patient carrying BCR::ABL1 splicing variant did not experience blast crisis for 15 years without responding to various TKIs Nakamura F et al. Intern Med, February 2025 – open access publication
|
Circumventing imatinib resistance in chronic myeloid leukemia: Novel Telmirsatan-based cell death modulators with improved activity and stability Gebhart M et al. Eur J Med Chem, February 2025 – open access publication |
Ophthalmic findings leading to diagnose chronic myeloid leukemia: A multimodal image case report Hoyos A et al. Eur J Ophthalmol, February 2025 (epub ahead of print) |
Proliferation inhibited by Genipin in human leukemia K562 cells: Involvement of uncoupling protein 2 in mitochondrial damage Zhou Y et al. World J Oncol, February 2025 (epub ahead of print) – open access publication
|
Asciminib in the treatment of chronic myeloid leukemia chronic phase – Review Costa A et al. Future Oncol, February 2025 (epub ahead of print) |
CML with mutant ASXL1 showed decreased sensitivity to TKI treatment via upregulation of the ALOX5-BLTR Signaling Pathway Miyashita N et al. Cancer Sci, February 2025 (epub ahead of print) – open access publication |
A nomogram for predicting T315I-free survival in chronic-phase chronic myeloid leukemia patients: A multicentre retrospective study Hu SW et al. Sci Rep, February 2025 – open access publication |
|
Introduction to a series of reflections on a quarter century of TKIs for CML Druker BJ. Blood, February 2025 – open access publication |
|
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1 / 2 trial Cortes JE et al. Lancet Haematol, February 2025 (epub ahead of print) |
|
Blast-phase chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia Shuyu E et al. Am J Clin Pathol, February 2025 |
|
Inflammatory/immune adverse events in chronic myeloid leukemia patients during treatment with Bosutinib Agostani E et al. Cancer Med, February 2025 – open access publication |
|
Total psoriasis regression in a patient with chronic myeloid leukemia treated using Nilotinib Horňák T et al. Ann Hematol, February 2025 (epub ahead of print) – open access publication |
|
Fibrosis and treatment-free remission in chronic myeloid leukemia Brailovski E et al. Br J Haematol, February 2025 (epub ahead of print) |
|
BCR::ABL1 deep molecular response quantification and transcript type identification in chronic myeloid leukemia using a US Food and Drug Administration-approved droplet-based PCR assay Kockerols C et al. J Mol Diagn, February 2025 – open access publication |
|
Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia Abumiya M et al. Int J Hematol, February 2025 (epub ahead of print) – open access publication |
|
Treatment-free remission outcomes in BCR::ABL1 digital PCR selected clinical cohort of chronic myeloid leukemia patients Kockerols C et al. Eur J Haematol, February 2025 (epub ahead of print) – open access publication |
|
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukemia Gong X et al. Leukemia, February 2025 (epub ahead of print) – open access publication |
|
Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia Chen EY et al. Eur J Haematol, February 2025 – open access publication |
|
January 2025 |
Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: A phase 1b randomized clinical trial Jabbour E et al. JAMA Oncol, January 2025
|
Design and fabrication of novel microfluidic-based droplets for drug screening on a chronic myeloid leukemia cell line Jaafari N et al. PLoS, January 2025 – open access publication
|
Real-world experience in the management of chronic myeloid leukemia patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life Cho HJ et al. Acta Haematol, January 2025 (epub ahead of print)
|
Exploring the significance of MDM2 gene promotes variants in chronic myeloid leukemia Fontecha MB et al. Leuk Res, January 2025 (epub ahead of print)
|
Bosutinib for the treatment of CML – using it safely: a Podcast Lipton JH and Cortes JE. Target Oncol, January 2025 (epub ahead of print) – open access publication |
N-Degron PROTACs as a potential therapeutic approach for chronic myeloid leukemia Hohmann G & Eldeeb MA. Anticancer Agents Med Chem, January 2025 (epub ahead of print)
|
The evolution of treatment-free remission Hughes TP et al. Blood, January 2025 (epub ahead of print) |
Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL positive leukemia Luo Z et al. Cancer Res, January 2025 – open access publication
|
The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia Qian Z et al. Bioorg Chem, January 2025 (epub ahead of print) |
Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both imatinib-sensitive and imatinib-resistant CML cells Sun X et al. Biochem Pharmacol, January 2025 (epub ahead of print)
|
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukemia: Are women and men different? Maduado C et al. ESC Heart Fail, January 2025 (epub ahead of print) – open access publication |
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia Minhajuddin M et al. Haematologica, January 2025 – open access publication |
Efficacy and safety of the first-in-class STAMP inhibitor asciminib in patients with chronic myeloid leukemia – Review Ureshino H and Kimura S. Clin Lymphoma Myeloma Leuk, January 2025 |
LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting Quijada-Alamo M et al. Haematologica, January 2025 – open access publication |
Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia Li Z et al. Cancer, January 2025 – open access publication |
Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia Komic H et al. Haematologica, January 2025 – open access publication |
Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib Yu L et al. Cancer, January 2025 – open access publication |
High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell toxicity in chronic myeloid leukemia Nygren PJ et al. Blood, January 2025 (epub ahead of print) |
Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid) Sasaki K. Cancer, January 2025 |
Tyrosine kinase inhibitor therapy enhances stem cells profile and may contribute to survival of chronic myeloid leukemia stem cells Rocco S et al. J Clin Med, January 2025 – open access publication |
Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors Kondo T et al. Cancer, January 2025 – open access publication |
EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in chronic myeloid leukemia Brunmeier R et al. Leukemia, January 2025 (epub ahead of print) – open access publication |
Impact of first- and second-generation tyrosine kinase inhibitors on the development of graft-versus host disease in individuals with CML: A retrospective analysis on behalf of the Polish Adult Leukemia Group Giordano U et al. Biomedicines, January 2025 - open access publication |
|
Clinical and prognostic significance of additional chromosomal abnormalities at diagnosis of chronic myeloid leukemia Mayer J et al. Am J Hematol, January 2025 (epub ahead of print) – open access publication |
|
Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases Yousefi A et al. Ann Hematol, January 2025 (epub ahead of print) – open access publication |
|
Asciminib versus bosutinib following two or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study Szuber N et al. Future Oncol, January 2025 (epub ahead of print) – open access publication |
|
Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice Aleem A et al. Clin Lymphoma Myeloma Leuk, January 2025 |
|
Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on TKI therapy Shen Q et al. Leuk Lymphoma, January 2025 (epub ahead of print) |
|